He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and has been Chief Investigator of several phase II / III trials of novel endocrine based therapeutic approaches in both advanced and early stage disease, including one of the large global adjuvant CDK 4/6 inhibitor studies in early breast cancer.
He has published over 260 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of various scientific committees and international advisory boards, has served as Faculty Member at the American Society for Clinical Oncology and is currently on the Scientific Committee in the European Society for Medical Oncology.